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Abstract
Hypothyroidism is an endocrine disorder whose management raises many challenges in
clinical practice. Its standard treatment is levothyroxine (LT4). The goal of the treatment
is to normalize signs and symptoms, as well as to achieve thyroid-stimulating hormone
(TSH) concentrations within the reference range, on an individual basis. It is known that
5–10% of hypothyroid patients remain symptomatic, despite achieving the target TSH
levels, which, in turn, affects their quality of life. After ruling out other causes of non-
thyroid origin for this persistence, it is suggested that these patients could benefit from
the  use  of  liothyronine  (LT3),  added  to  LT4,  especially  if  polymorphism  of  the
deiodinase  2  (D2)  genes  is  documented.  There  exist  a  variety of  LT3 preparations,
whose concentrations vary from 5 to 50 ug, with the recommended LT4/LT3 ratio of
13:1–20:1. The goals of combination therapy should be to achieve a physiological ratio
of free triiodothyronine/free thyroxine (FT3/FT4) and non-suppression of TSH. Because
there is currently no guide that makes evidence-based recommendations on the use of
LT3 in primary hypothyroidism, more clinical studies are needed to be able to identify
hypothyroid  patients  who  may  benefit  from  the  use  of  LT3,  by  identifying  new
biomarkers.
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Introduction
Hypothyroidism, especially primary hypothyroidism, has been identified as one of the
most common endocrine pathologies, affecting 3% of the general population, of which
5.1% are women and 0.9% men [1]. In Latin America, the estimated prevalence is 10%
[2], and there are no current studies on the epidemiology of this disease in our country.
Before  the  1970s,  both  liothyronine  (LT3)  and  levothyroxine  (LT4)  combined  with
thyroid hormone replacement therapy and desiccated thyroid extract (DTE) were widely
prescribed.  However,  the  discovery  that  thyroxine  (T4)  is  largely  converted  to
triiodothyronine  (T3)  outside  the  thyroid,  within  target  tissues,  and  concerns  about
dosage and stability of free T3 (FT3) profiles in patients treated with LT3 or DTE have
made  LT4  the  standard  therapy  for  almost  50  years  [3].  No  expert  guidance  or
recommendation has suggested thyroid hormone replacement with LT3 alone, but the
debate has been whether combined therapy with LT4 and LT3 might be better than LT4
alone.
It  has  been  found  that  5–10%  of  hypothyroid  patients  receiving  LT4  continue  to
experience disabling  symptoms such as  fatigue,  depression,  and impaired  cognition,
despite being adequately replaced biochemically, affecting their quality of life [4]. In a
study that aimed to evaluate satisfaction and quality of life (QOL) in 969 hypothyroid
patients through a survey, it was found that 77.6% were dissatisfied, and the scores of
QOL were low. Furthermore, combined treatment of LT4 + LT3 or with DTE was found
to  be  associated  with  a  better  QOL  compared  to  LT4  monotherapy.  However,
multivariate  analysis  failed  to  confirm  an  association  between  the  type  of  thyroid
hormone treatment and QOL or satisfaction [5]. In addition, Peterson et al. performed
an online survey for 12,146 hypothyroid patients and found, strikingly, that individuals
taking DTE reported a higher median treatment satisfaction of 7 out of 10, the LT4
treatment group exhibited satisfaction of 5, and for the LT4 + LT3 treatment group the
satisfaction  level  was  6.  These  results  suggest  that  LT4+LT3  treatment  is  still  not
satisfactory, but more studies are needed to confirm this finding [6].
However, due to the controversy over whether hypothyroid patients can be optimally
treated  with  LT4  alone,  numerous  studies  over  time  have  addressed  the  potential
benefits  of  combination  therapy,  but  these  have  been  inconclusive.  Recent  genetic
studies have shown the importance of deiodinases in maintaining the euthyroid state, as
well  as  the  growing  evidence  of  polymorphisms  of  these,  which  would  affect  the
conversion of T4 to T3 [7], providing a solid argument for the addition of LT3 to the
therapy.
Regarding the benefits of LT3, a study compared LT3 therapy with LT4 therapy and
demonstrated the benefits of LT3 therapy, i.e. weight loss and favourable changes in the
lipid  profile,  which  could  be relevant  to  hypothyroid  patients  affected  by comorbid
conditions such as cardiovascular diseases, diabetes, dyslipidaemia, and obesity, where
weight control and lowering of serum cholesterol are particularly important [8].
However, currently, the prolonged use of LT3 can be a challenge because it needs to be
administered multiple times a day, which can affect adherence [8]; in addition, LT3 is
more expensive compared to LT4, which has caused a generalized variability in patient
access  to  it  [9].  Therefore,  it  is  important  to  select  patients  who  would  potentially
benefit from combined LT3 and LT4 therapy.
It  is  of  interest  that  systematic  and  comprehensive  research  have  demonstrated  the
potential  benefits  of  LT3 therapy,  because  endocrinologists  are  frequently consulted
about hypothyroid adult  patients  taking LT4 who are dissatisfied with their  therapy.
Therefore, once non-thyroid causes related to these symptoms have been excluded, the
patient and their doctor may consider some therapies, among them the use of combined
therapy  with  LT4  and  LT3,  whose  use  remains  controversial  because  it  bears
contradictory results in most published clinical trials [10].
Thus, in this article, we aimed to carry out an updated narrative review of the literature 
on the use of LT3 in the treatment of primary hypothyroidism, in order to establish 
which patients may be eligible for combined LT3 and LT4 therapy.
Pathophysiology
Thyrotropin-releasing  hormone  (TRH)-synthesizing  neurons  are  present  in  several
nuclei of the hypothalamus, but only hypophysiotrophic TRH neurons, located in the
paraventricular nucleus, have been determined to be involved in the regulation of the
hypothalamic-pituitary-thyroid  (HPT)  axis  [11].  TRH  stimulates  the  synthesis  and
release of TSH in the thyrotrophic cells of the adenohypophysis, where it is transported
through the pituitary portal system. TSH, in turn, stimulates thyroid follicular cells to
release T4 (80%) and T3 (20%) [12].
The  negative  feedback  of  thyroid  hormones  occurs  in  the  pituitary  and  in  the
hypothalamus;  consequently,  the  production  and  secretion  of  TSH  and  TRH  are
regulated  by the  levels  of  circulating  thyroid  hormones.  In  this  way,  the  HPT axis
regulates the concentration of thyroid hormones [11, 13].
Thyroid hormones are then transported into the cells in order to exert their effects. Once
transported, only T3 binds to the thyroid hormone receptor in the nucleus, while the pro-
hormone T4 needs  to  be converted into  active hormone T3 by deiodinases  [11].  In
euthyroid individuals, the peripheral conversion of T4 to T3 accounts for 80% of the T3
produced [12].
The deiodination of thyroid hormone is often catalysed by the family of selenoenzymes
called deiodinases (D) (Tab. 1), which comprises three enzymes: type 1 (D1), type 2
(D2), and type 3 (D3) [11]. Both the inner ring (phenolic) and the outer ring (tyrosyl) of
T4 can be deiodinated, which ultimately leads to the formation of 3,3'-diiodotyrosine.
The key to this process is the action of deiodinases that are subspecialized in different
tissues. Most of the T3 in the circulation is derived from the actions of D1 in the liver,
kidneys, and thyroid [11]. However, in the hypothalamus and pituitary thyrotroph, D2
allows  the  feedback  loop  to  recognize  T4  concentrations  because  T4  is  rapidly
converted to T3 in these cells [14]. In the nuclei of the anterior pituitary, approximately
half  of the T3 bound to nuclear receptors is  derived from circulating T3,  while  the
remaining half is derived from the intrahypophyseal conversion of T4 to T3 [11].
The major steps in the actions of T4 are initiated by the entry of T4 into the cell, which
is now recognized to be controlled by the expression of various membrane transporters
for thyroid hormones [11, 13, 15]. Then, it must be converted to T3 in cells that express
D1 or D2, allowing a dual source of T3 (systemic and local) to the HPT axis. After
transport into the cell, cytosolic T3 then enters cell nuclei on the HPT axis by pathways
yet  to  be  defined;  then,  it  binds  to  high-affinity  chromatin-bound  proteins,
predominantly the thyroid hormone receptor β2 [10]. Due to the rapid generation of T3
from T4  within  these  cells  by D2,  the  cytosolic  T3  concentration  is  higher,  and  it
remains in a static imbalance with serum T3 [11].
D3 inactivates T3 and is vital during growth and development and later in adult life,
because D3 is involved in the development of the placenta, uterus, and embryo/foetus,
protecting  it  from maternal  T3 and T4.  This  allows  the  autonomous  developmental
program in the embryo and foetus to control the differentiation process [11, 13, 15].
Several  single-nucleotide  polymorphisms  have  been  identified  in  the  genes  for
deiodinases,  and  relationships  between  hormone  levels  have  been  investigated.
Theoretically, polymorphisms could result in lower enzyme activity and therefore lower
conversion of T4 to T3 in the periphery, with even small changes in hormone levels that
have important long-term consequences [16].
The D1 (Cys785Thr) polymorphism is associated with higher T4 and reverse T3 (T3r)
and  lower  T3  in  plasma,  suggesting  decreased  D1  activity.  Conversely,  the  D1
(Ala1814Gly) polymorphism has been associated with increased plasma T3 levels and a
higher  T3:T3r  ratio,  which  suggests  greater  D1  activity.  In  particular,  the  D3
(Thr154Gly) polymorphism does not affect the plasma levels of thyroid hormones [17].
The D2 polymorphism (Thr92Ala) is associated with a high T4, a lower T3 in plasma,
and a lower T3:T4 ratio, suggesting decreased D2 activity. It is the most investigated
because of its clinical relevance. There are several reports that describe its association
with clinical syndromes that include hypertension, type 2 diabetes, mental disorders,
lung injury, bone turnover, and autoimmune thyroid disease [18]. Studies in pituitary
cell and skeletal muscle cell cultures demonstrated that the Thr92Ala enzyme is less
efficient in converting T4 to T3. In a study conducted using knock-in mouse models,
Thr92Ala-substituted mice manifested hypothyroidism in different areas of the brain,
which  reversed  with  LT3  administration  [17].  Additionally,  the  presence  of  the  D2
polymorphism (ORFa-Gly3Asp) has been found to be associated with reduced levels of
T4 and reverse T3 (rT3);  consequently,  they generate  an increase in  the T3:T4 and
T3:rT3 ratio, conditions that reflect an increase in D2 activity [17].
Individuals  with  such polymorphisms  would  potentially  require  LT3 replacement  to
achieve  euthyroidism.  However,  there  remains  no  clear  evidence  supporting  the
relationships  between  D2  gene  polymorphisms,  thyroid  parameters,  and  negative
clinical consequences [16].
Comparison of liothyronine vs. levothyroxine treatment
There  is  a  paucity  of  data  to  support  the  use  of  LT3.  However,  in  some  specific
situations,  they  can  provide  some  benefits.  In  hypothyroid  patients  with  type  2
deiodinase polymorphism, or who are athyreotic  19, they remain symptomatic despite
reaching the target range of the TSH level. Also, in patients with differentiated thyroid
cancer, they can be used temporarily for 3–4 weeks, before treatment with radioactive
iodine, thus shortening the duration of hypothyroidism [20]. LT3 monotherapy has been
shown to have metabolic benefits with improvement in weight, LDL cholesterol, mood
well-being, and psychometric functioning, as well as being better tolerated in high-risk
groups with dyslipidaemia and obesity [15, 21].
According to the results of previous studies, patients receiving LT4 replacement therapy
have a normal serum TSH, achieve higher total T4 and FT4 concentrations, and lower
total T3 and FT3 serum concentrations, compared to healthy controls [22]. FT3 values
below the lower limit  of normal are observed in approximately 15% of hypothyroid
patients in LT4 [23]. Therefore, it is questionable whether low serum T3 levels may be
involved in persistent patient discomfort, requiring higher doses of LT4 to normalize T3
levels.
The mechanism responsible for low serum T3 during LT4 therapy is related to D2. This
enzyme catalyses the conversion of T4 to T3 in extra thyroid tissues, thus maintaining
normal serum T3 levels during LT4 replacement therapy. D2 has a short half-life (60
minutes), which  becomes even shorter (20 minutes) upon interacting with T4, resulting
in ubiquitination of D2 and stimulation for its proteasomal degradation [24]. Therefore,
while,  in  the  rest  of  the  body,  the  production  of  T3 mediated  by D2 progressively
decreases with increasing doses of LT4, due to the ubiquitination of D2, this does not
occur in the hypothalamus/pituitary, where the dose of LT4 required to normalize TSH
is less than the dose that normalizes serum T3. It follows that to achieve a normal serum
T3 concentration, a relatively high dose of LT4 must be administered, which is likely to
suppress serum TSH [25], which then provides a justification for LT3 supplementation.
Studies  in  rats  required  a  combination  of  LT4  and  LT3  replacement  to  achieve
physiological tissue serum concentrations. However, similar studies in humans did not
appear  to  result  in  an  improvement  in  patient-reported  outcomes.  In  another  study,
serum  T4  and  T3  concentrations  were  not  different  between  responding  and  non-
responding patients to  LT3 therapy.  This may be because intracellular T3 levels are
dependent  on  several  factors,  including  membrane  transport  proteins,  deiodination,
nuclear protein binding (retinoid X receptor), and thyroid hormone receptors, which are
downregulated by serum levels of thyroid hormones [26].
Meta-analyses have compared the use of LT3 alone or in combination with LT4, against
LT4 alone, demonstrating that there is no consistent benefit on the use of LT3 over LT4
alone and that there is no difference in terms of adverse effects. Current forms of oral
LT3  cause  transient  unphysiological  elevated  serum T3  concentrations  after  dosing,
which are not believed to cause low serum TSH concentrations but still may be harmful.
More flexible dosing regimens of LT3, with the help of the introduction of 5-ug tablets,
make its dosing easier and potentially safer, if they reduce the risk of increased serum
T3 [26].
LT3 monotherapy appears more favourable for patients affected by dyslipidaemia and
obesity,  but  there  is  insufficient  evidence  to  suggest  its  superiority to  standard LT4
therapy, particularly due to the need for strict adherence to the regimen and timing of
drug administration, the risk of overdosing or underdosing, and the risk of cardiac and
skeletal toxicity. Therefore, the careful and judicious use of LT3 may be indicated in
some patients who continue to report  adverse symptoms that cannot be attributed to
another cause [27].
Comparison of combined levothyroxine + liothyronine therapy vs. levothyroxine
monotherapy
Generally, the rationale for LT4 treatment is that both D1 and D2 convert T4 to T3, thus
restoring the T3 pool and clinical euthyroidism [28].
However,  as  previously explained,  LT4 therapy in hypothyroid  rats  did not  achieve
normal serum T3 levels, nor did it result in normal T3 levels in all tissues sampled, but
it  did  show  restoration  of  normal  tissue  concentrations  of  thyroid  hormones  with
combined therapy with LT4 and LT3 [21, 28].
Therefore,  in murine models,  TSH secretion has been noted to normalize before T3
levels are fully restored in plasma and other tissues,  resulting in low circulating T3
levels and “tissue hypothyroidism”. The use of combined therapy with LT4 and LT3 in
hypothyroid rats  has also normalized serum TSH; moreover,  it  also corrects  the T3
deficiency in peripheral tissues. Consistent with this, markers of euthyroidism, such as
serum cholesterol  levels,  mitochondrial  content,  and enzymatic  activity in  liver  and
skeletal muscle, were closer to values in control rats when administration of LT4 and
LT3 was sustained [25].
These conclusions  reveal  doubts  about  human replacement  therapy with LT4 alone,
because it may not be able to restore euthyroidism in all tissues of hypothyroid patients
[28].
It is well established that there are two changes in thyroid hormone levels that occur in
hypothyroid  patients  receiving  LT4  monotherapy.  These  changes  are  as  follows:
increased FT4 levels and increased FT4/T3 ratio (often associated with a decrease in T3
or FT3 levels). Depending on the study, mean serum T3 or FT3 levels may be in the
lower half of the normal range, and levels may even be below the normal range in up to
15% of individuals [15, 29, 30, 31].
All these differences have been noted to occur despite comparable serum TSH levels. In
fact,  in a  cross-sectional  study based on the data  from the US National  Health and
Nutrition Examination Survey, the serum levels of T3 and FT3 were 10% lower in LT4-
treated patients than in a control group matched for sex, age, ethnicity, and TSH levels
[32]. Therefore, although LT4 therapy is significantly effective in normalizing serum
TSH levels, it fails to restore euthyroidism in some tissues, based on several metabolic
parameters such as serum cholesterol levels and other biomarkers that remain abnormal
in patients treated with LT4, despite normal serum TSH [32–34].
To  date,  13  randomized  clinical  trials  (RCTs)  have  been  published  comparing  the
efficacy of  combined LT4 and LT3 therapy with LT4 monotherapy [9].  Four  meta-
analyses  of  these  combination  therapy  trials  found  no  clear  benefit  over  LT4
monotherapy in terms  of  mood,  health-related  quality of  life,  or  cognitive function.
These data have been taken to suggest that at the population level, there is no benefit of
using  combination  therapy  over  monotherapy.  However,  none  of  the  studies  have
achieved physiological replacement [3].
It is noteworthy that Wiersinga et al. reviewed the five crossover trials and identified
that,  despite  adequate  blinding,  48%  of  all  hypothyroid  patients  preferred  the
combination  of  LT3  and  LT4,  27%  preferred  LT4  monotherapy,  and  25%  had  no
preference [35].  Additionally,  studies  in  which low or low normal TSH levels  were
often achieved reported benefits. Although this has been taken to suggest an overdose,
the  lower  TSH  levels  may  be  related  to  the  non-physiological  nature  of  the  LT3
replacement [3, 26]. 
In general, it should not be assumed that combination therapy has no advantages over
monotherapy until a well-designed long-term trial of combined physiological therapy
with a sustained-release preparation or a dose of T3 three times a day is performed [3].
On the other hand, currently, all clinical practice guidelines agree that LT4 monotherapy
should remain the treatment of choice in hypothyroid patients [35].
Candidates for combined levothyroxine + liothyronine therapy
It is necessary to ask whether there is any consensus from international associations
regarding these emerging controversies about LT4 + LT3 combination therapy.
The European Thyroid Association (ETA) guidelines in 2012 [19] and the American
Thyroid Association (ATA) guidelines in 2014 [15] both suggested that combination
therapy  with  LT4  and  LT3  could  be  considered  as  an  experimental  approach  in
hypothyroid patients treated with LT4, who have persistent complaints despite having
serum TSH values within the reference range, provided coexisting autoimmune diseases
have been ruled out [35].
It is important to note that for women of childbearing age using combined LT4 and LT3
therapy, foetal neurogenesis is primarily dependent on maternal FT4 levels at up to 16–
18 weeks of gestation; therefore, regimens containing an excessive amount of LT3 can
cause  hypothyroxinaemia,  which  would  then  be  associated  with  impaired  foetal
neurodevelopment [36]. There is insufficient data on foetal consequences of LT4 + LT3
combination  therapy in  pregnant  women.  Consequently,  it  seems  prudent  for  safety
reasons to refrain from combination therapy in pregnant women [19].
There is still concern about the long-term safety of LT4 + LT3 combination therapy,
including cardiovascular safety,  because ETA guidelines in 2012 established that the
increase of serum-free T3 may provoke cardiac arrhythmias in susceptible patients [19].
However, the results of a 17-year population-based observational study based on the use
of LT3 in Scotland have been reassuring. Compared with patients taking LT4 alone (n =
33,955),  those  using LT3 (with  or  without  LT4,  n  = 400)  had no increased  risk of
cardiovascular disease, atrial fibrillation, or fractures after adjusting for age [35]. In a
long-term cohort study conducted in Sweden, the use of LT3 did not lead to an increase
in the incidence of breast cancer, the incidence of any cancer, and all-cause mortality
compared to the use of LT4. Surprisingly, there was evidence of lower mortality in LT3
users  after  dose  adjustment,  which  was  potentially  attributed  to  an  artifact  of  the
underlying associations between dose and patient diagnosis [37].
Recent Italian guidelines support the ETA and ATA guidelines. Furthermore, they were
able  to  establish that  combined therapy may be  indicated in  thyroidectomized adult
patients with persistent symptoms of hypothyroidism and postoperative serum T3 levels
and a FT4/FT3 ratio lower than their preoperative values during LT4 monotherapy. The
LT4 +  LT3 dose  during  combination  therapy should  be  between  13:1  and  20:1  by
weight. To avoid possible adverse effects, the starting dose should be approximately
17:1 [38].
If  a  trial  of  combination  therapy is  being  considered  in  an  individual  patient,  it  is
important to set clear expectations [39]. These include explaining that this is a non-
standard  treatment  for  which  the  risks  remain  unclear,  with  the  potential  risk  of
accelerated  osteoporosis,  atrial  fibrillation,  and  stroke.  Likewise,  it  is  important  to
emphasize the importance of adherence with medication and follow-up [17].
Furthermore,  it  should  be  clear  that  this  is  a  potentially  non-standard  therapy with
significant  monetary  cost,  and  treatment  will  be  discontinued  if  no  benefit  is
experienced within a reasonable period, i.e. 3–6 months [19].
On  the  other  hand,  the  NICE (The  new National  Institute  for  Clinical  Excellence)
guideline does not recommend routinely offering LT3 for patients with hypothyroidism,
alone or in combination with LT4, because there is insufficient evidence proving its
benefits  over  LT4  monotherapy,  and  long-term  adverse  effects  are  uncertain.  The
guideline does not give a clear recommendation on the use of LT3, but it thus suggests
that it may play a role in patients with symptoms of hypothyroidism despite adequate
replacement with LT4, and that further investigation is required [26, 40].
Genetic  variations  in  deiodinases  are  associated  with  altered  thyroid  function  and
adverse  health  outcomes  [41].  Individuals  with  genetic  variants  in  D2 [42]  and the
thyroid  hormone  transporter  protein  MCT10  [43]  have  shown  a  preference  for
combined  LT4  +  LT3  therapy  with  an  additive  effect.  However,  these  studies  had
limitations  due  to  multiple  tests  and  small  sample  size.  The  discovery  of  the
polymorphism of the D2 gene (Thr92Ala), including its association with subtle changes
in thyroid hormone homeostasis, quality of life index, and response to combined LT4 +
LT3 therapy, has sparked enthusiasm as a possible explanation of patient dissatisfaction
[3]. By contrast, Appelhof et al. determined genotypes for D2-orfA-Gly3Asp and D2-
Thr92Ala  polymorphisms  in  141  patients  with  primary  hypothyroidism,  adequately
treated with levothyroxine monotherapy, and found that these polymorphisms do not
explain differences in well-being, neurocognitive functioning, or appreciation of T4/T3
combination therapy in patients treated for hypothyroidism.  
In this way, alternative strategies, such as a single-nucleotide polymorphism panel or the
use  of  thyroid  hormone  metabolites  or  metabolomics,  may  provide  a  better
understanding of thyroid status in tissues [3, 8].
A  consensus  (ETA-2021)  has  recently  been  established  on  evidence-based
recommendations  on  the  use  of  the  LT4  +  LT3  combination  in  the  treatment  of
hypothyroidism. This consensus describes the criteria that patients must meet in order to
be  recruited  and  tested  for  combination  therapy.  After  excluding  other  causes  of
persistent  symptoms,  patients  who do not  report  relief  of  their  symptoms with LT4
therapy should be recruited. Also, patients must be treated with at least 1.2 µg/kg/day of
LT4 to be eligible, and patients who have low baseline levels of total serum T3 while
taking LT4 monotherapy should be included in the tests, and results should be stratified
according to the change in total T3 levels achieved with the combination therapy. On the
other  hand,  they  recommend  the  use  of  validated  thyroid-related  quality  of  life
questionnaires (PRO and ThyPRO-39), which should be used in assessing the baseline
level of dissatisfaction, and they suggest that future trials of combination therapy should
consider including the genotyping of polymorphisms and must have adequate power to
study the effect of this polymorphism on the results of the study [9].
The authors of the present narrative review propose a treatment algorithm, profiling the
hypothyroid patient who could receive LT3 (Fig. 1).
Dose,  monitoring,  and  preparations  to  be  used  in  combined  therapy  with
levothyroxine and liothyronine
A wide range of LT3 preparations are available, with tablet concentrations ranging from
5 to 50 µg. ETA guidelines recommend an initial ratio of 13:1–20:1 (LT4:LT3), which
represents a dose of 5 or 10 µg of LT3 for patients taking 100–200 µg of LT4. Cutting
LT3 pills with a pill cutter would allow twice-a-day dosing, such as 2.5 ug twice a day.
Initially, the LT4 dose is usually reduced by 12.5 or 25 ug in order to accommodate the
addition  of  LT3.  The  therapeutic  substitution  of  LT3  for  LT4  has  previously  been
calculated to approximately 1:3 ratios [38, 45].
A simple method (Tab. 1) to arrive at the desired dose relationship between LT4 and
LT3 is as follows: Dose “x” is the daily dose of LT4 in µg that results in a normal serum
TSH value. The required daily dose of LT3 in µg (called “y”) is given by y = x:20. The
required daily dose of LT4 in µg (called “z”) is given by z = x − 3y. Considering that
LT4  can  be  administered  once  a  day,  the  daily  dose  of  LT3  should  be  divided,  if
possible, into two doses, i.e. one before breakfast and the larger one before sleeping.
The rationale for dividing the daily dose of LT3 is the relatively short half-life of LT3,
peak serum T3 values 2–4 h after ingestion, and a physiological diurnal variation in
serum T3 with the zenith around 4 a.m. and nadir between 3 and 5 p.m. [35].
The ETA guideline (2012) recommends using LT4 tablets separate from LT3 tablets in
combination therapy, because the combination tablets contain a LT4:LT3 dose ratio of
4:1, 5:1, and 10:1; these ratios are significantly different from the recommended ratios
of 13:1–20:1. If dose adjustments are necessary, it is also more convenient to change the
dose of only one of the components, preferably LT3 [35].
Regarding the duration of treatment with the combination therapy, there exists very little
evidence; the RCTs ranged from 5 to 52 weeks [45]. Currently consensus recommends
that  it  would be  reasonable  to  run a  trial  for  at  least  1  year,  with interim outcome
assessments at 3 and 6 months [8]. The fixed-term nature of the trial should be agreed
with  the  patient  before  commencing,  and  there  should  be  agreement  that  LT4
monotherapy will once again be the mainstay treatment if no significant benefit is seen
[46].
Monitoring  is  challenging  due  to  variations  in  serum  T3  levels  with  current
preparations. If the serum T3 peak (2–4 hours post-dose) is within reference values and
TSH is not suppressed, it is probably a safe dose, although not all patients are satisfied
in  this  range  [5].  The  goal  of  the  LT4:LT3  combination  should  be  to  achieve  a
physiological  T4/T3  ratio  [35].  For  patients  in  whom there  is  a  long-term plan  to
continue treatment with LT3, monitoring of the regularity of the pulse and the conduct
of an electrocardiogram to rule out atrial fibrillation are recommended at each medical
visit, together with a bone densitometry in postmenopausal women every 3 years [9].
Response is commonly assessed through the patient’s self-reporting of improvement,
although questionnaires are used by some clinicians, e.g. ThyPRO. It is important to
assess the response to be able to stop treatment if it is not effective or if the effect has
been lost over time [9].
Conclusion
Combination  therapy with  LT3  and  LT4  should  be  individualized  for  patients  with
primary hypothyroidism who receive LT4, those who have a target TSH concentration,
and those with persisting symptoms, assessing its risks/benefits. Likewise, more studies
are needed to be able to identify subgroups of hypothyroid patients who may benefit
from  the  use  of  LT3,  in  addition  to  treatment  with  LT4,  probably  through  the
identification of new biomarkers or genetic polymorphisms.
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Table 1. Main characteristics of deiodinases type 1, 2, and 3
D1 D2 D3
Preferred substrate T3r T4 T3








Cellular localization Plasma membrane Endoplasmic
reticulum
Plasma membrane
Hyperthyroidism ↑ ↓ ↑
Hypothyroidism ↓ ↑ ↓
Selective activator None cAMP Hypoxia
Selective inhibitor Propylthiouracil None None








main clearance of T3 
CNS — central nervous system; cAMP — cyclic adenosine monophosphate; rT3 — reverse T3
Table 2. Practical method to calculate the appropriate dose of levothyroxine (LT4) and 
liothyronine (LT3) in eligible patients for combination therapy
LT4 dose that
normalizes TSH = X
X= 50 µg X = 100 µg X = 150 µg  
LT3 dose = Y
Formula: Y = X/20
2.5 µg 5 µg 7.5 µg
LT4 dose = Z
Formula: Z = X-3Y
42.5 µg 85 µg 127.5 µg
Rounded LT4 dose 50 µg 88 µg 125 µg
Ratio LT4/LT3 17:1 17:1 17:1
. 
Figure 1. Diagnostic and therapeutic algorithm of when to consider a patient with 
hypothyroidism as a candidate for the use of combined therapy with levothyroxine (LT4) and 
liothyronine (LT3). RA — rheumatoid arthritis; SLE — systemic lupus erythematous; SS — 
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